AU1306099A - Antihyperlipidemic statin-lp(a) inhibitor combinations - Google Patents

Antihyperlipidemic statin-lp(a) inhibitor combinations Download PDF

Info

Publication number
AU1306099A
AU1306099A AU13060/99A AU1306099A AU1306099A AU 1306099 A AU1306099 A AU 1306099A AU 13060/99 A AU13060/99 A AU 13060/99A AU 1306099 A AU1306099 A AU 1306099A AU 1306099 A AU1306099 A AU 1306099A
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
statin
kit
pharmaceutical composition
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU13060/99A
Other languages
English (en)
Inventor
Charles Larry Bisgaier
Roger Schofield Newton
Randy Ranjee Ramharack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of AU1306099A publication Critical patent/AU1306099A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU13060/99A 1997-12-12 1998-11-04 Antihyperlipidemic statin-lp(a) inhibitor combinations Abandoned AU1306099A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6943297P 1997-12-12 1997-12-12
US60069432 1997-12-12
PCT/US1998/023480 WO1999030706A1 (fr) 1997-12-12 1998-11-04 Compositions antilipemiques combinant un inhibiteur de lipoproteine (a) et une statine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2003244047A Division AU2003244047A1 (en) 1997-12-12 2003-08-29 Antihyperlipidemic stain-Lp(a) inhibitor combinations

Publications (1)

Publication Number Publication Date
AU1306099A true AU1306099A (en) 1999-07-05

Family

ID=22088939

Family Applications (2)

Application Number Title Priority Date Filing Date
AU13060/99A Abandoned AU1306099A (en) 1997-12-12 1998-11-04 Antihyperlipidemic statin-lp(a) inhibitor combinations
AU2003244047A Abandoned AU2003244047A1 (en) 1997-12-12 2003-08-29 Antihyperlipidemic stain-Lp(a) inhibitor combinations

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2003244047A Abandoned AU2003244047A1 (en) 1997-12-12 2003-08-29 Antihyperlipidemic stain-Lp(a) inhibitor combinations

Country Status (14)

Country Link
EP (1) EP1037623A1 (fr)
JP (1) JP2003524582A (fr)
KR (1) KR20010033017A (fr)
AU (2) AU1306099A (fr)
BR (1) BR9813539A (fr)
CA (1) CA2299397A1 (fr)
HU (1) HUP0100349A3 (fr)
IL (1) IL134364A0 (fr)
IS (1) IS5385A (fr)
NO (1) NO20002965L (fr)
NZ (1) NZ502874A (fr)
PL (1) PL343851A1 (fr)
WO (1) WO1999030706A1 (fr)
ZA (1) ZA9811349B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998030231A1 (fr) 1997-01-07 1998-07-16 Amylin Pharmaceuticals, Inc. Utilisation d'exendines et de leurs agonistes pour reduire la consommation alimentaire
EP1076091A1 (fr) * 1999-08-09 2001-02-14 Universite Catholique De Louvain Composé ou composition pharmaceutique pour la prévention et/ou le traitement d'ischémie cardiaque, de maladies vasculaires périphériques, de tumeurs et de plaies
US20030036504A1 (en) * 2000-01-10 2003-02-20 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
CA2399396A1 (fr) * 2000-02-10 2001-08-16 Yasuo Sugiyama Inhibiteurs de tnf-.alpha.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2016467A1 (fr) * 1989-06-05 1990-12-05 Martin Eisman Methode de traitement de l'atherosclerose des vaisseaux peripheriques a l'aide d'un inhibiteur de l'hmg coa reductase et (ou) d'un inhibiteur de la squalene synthetase
AU3473193A (en) * 1992-01-17 1993-08-03 Procter & Gamble Company, The Treatment for atherosclerosis
WO1993016690A1 (fr) * 1992-02-25 1993-09-02 Warner-Lambert Company Compositions cytoprotectrices contenant du pyruvate et des antioxydants
US5720963A (en) * 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
EP0738510A3 (fr) * 1995-04-20 2005-12-21 L'oreal Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes
CA2251972A1 (fr) * 1996-04-17 1997-10-23 Merck & Co., Inc. Therapie combinatoire pour reduire les risques associes a une maladie cardiovasculaire
NZ503982A (en) * 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus

Also Published As

Publication number Publication date
EP1037623A1 (fr) 2000-09-27
PL343851A1 (en) 2001-09-10
WO1999030706A1 (fr) 1999-06-24
IL134364A0 (en) 2001-04-30
ZA9811349B (en) 1999-06-14
HUP0100349A3 (en) 2002-02-28
JP2003524582A (ja) 2003-08-19
KR20010033017A (ko) 2001-04-25
CA2299397A1 (fr) 1999-06-24
IS5385A (is) 2000-02-25
AU2003244047A1 (en) 2003-09-25
HUP0100349A2 (hu) 2001-07-30
NO20002965D0 (no) 2000-06-09
NZ502874A (en) 2004-03-26
BR9813539A (pt) 2000-10-10
NO20002965L (no) 2000-06-09

Similar Documents

Publication Publication Date Title
AP1207A (en) Combination therapy.
JP2004210797A (ja) アムロジピン及びアトルバスタチンを含む治療用の組み合わせ
EP1045691B1 (fr) Combinaisons de statine-carboxyalkylether
US20070149578A1 (en) Combination Therapy
US20140012042A1 (en) Calcium Dicarboxylate Ethers
AU1306099A (en) Antihyperlipidemic statin-lp(a) inhibitor combinations
US20020103252A1 (en) Statin-carboxyalkylether combinations
EP1280522B1 (fr) Combinaison de carboxyalkylethers avec des agents antihypertenseurs et leur utilisation
US20040092574A1 (en) Statin-Lp(a) inhibitor combinations
MXPA00002105A (en) Antihyperlipidemic statin-lp(a) inhibitor combinations
EP1481962A1 (fr) Nouveau carboxyéthylether reduisant la cholesterolémie
US20030225123A1 (en) Antihypertensive agents and use
MXPA00002104A (en) Carton with panel locking means
MXPA00002085A (en) Combination therapy comprising amlodipine and a statin compound

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted